Gather the best of the crowd to create the third summit forum in the field of oncology | Fosun Pharma

In order to review the development process of China's oncology field, look forward to the future direction, and explore the road of cancer prevention and treatment in Healthy China 2030, the 3rd Oncology Summit Forum organized by Fosun Pharma was grandly opened on September 17, 2022, and domestic oncology experts gathered in the cloud to jointly draw a new blueprint
for cancer prevention and treatment in China.

Set sail: The Focus Summit kicks off

The conference was co-chaired by Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Zhou Jian of Zhongshan Hospital Affiliated to Fudan University, Professor Xu Ruihua of Sun Yat-sen University Cancer Hospital and Professor Shi Yuankai of Cancer Hospital of Chinese Academy of Medical Sciences
.

Professor Ma Jun, Professor Zhou Jian, Professor Xu Ruihua and Professor Shi Yuankai presided over (photo)

Professor Guan Zhongzhen of Sun Yat-sen Medical University Cancer Hospital, Academician Fan Jia of Zhongshan Hospital affiliated to Fudan University, Academician Yu Jinming of Shandong Provincial Cancer Hospital and Academician Teng Gaojun of Zhongda Hospital affiliated to Southeast University delivered opening speeches as honorary chairmen of the conference, and wished the conference a complete success
.

Speeches by Professor Guan Zhongzhen, Academician Fan Jia, Academician Yu Jinming and Academician Teng Gaojun (Photos)

After the chairmanship of Professor Wu Depei of the First Affiliated Hospital of Soochow University and the wonderful speech of Mr.
Wu Yifang, Chairman of Fosun Pharma, the Bureau and online colleagues witnessed the launch
of the Focus Summit Forum.

Moderated by Professor Ng Tak Pei (photo)

Speech by Mr.
Wu Yifang (photo)

Go all out: Create a new course of healthy China 2030 anti-tumor

Under the chairmanship of Professor Li Jin of the Dongfang Hospital Affiliated to Tongji University, the conference entered the academic session
.
Professor Liang Jun of Peking University International Hospital delivered a keynote speech
on "Creating a Healthy China 2030 Anti-tumor New Course".

Moderated by Professor Li Jin (Photo)

Professor Liang Jun said that at present, China's tumor incidence and mortality rate are still the first in the world, and aging and lifestyle changes have promoted the increase of tumor incidence in China
.
Based on this, colleagues in the field of oncology are facing difficulties and are committed to continuously improving people's healthy living standards
.
Under the joint effect of continuous improvement of national policies and continuous innovation of local enterprises, China's anti-tumor innovative drugs have experienced a difficult "metamorphosis" process from scratch, from imitation to innovation and internationalization, and have benefited more Chinese cancer patients
.
In the future, China's anti-tumor innovative drugs should be guided by clinical value and adopt a research and development strategy
combining "introduction + going out".
At the same time, colleagues in the field of oncology should also strengthen basic research, comprehensively explore the layout of new targets, and carry out differentiated clinical research to strengthen source innovation and improve the clinical research quality
of new anti-tumor drugs in China.

Report by Professor Liang Jun (Photo)

Summit Dialogue: Focus on the R&D of China's anti-tumor innovative drugs

Under the chairmanship of Professor Shen Lin of Peking University Cancer Hospital, Professor Wu Lingying of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Liang Jun of Peking University International Hospital, Professor Huang Huiqiang of Sun Yat-sen University Cancer Prevention and Treatment Center, Professor Zhang Li of Sun Yat-sen University Cancer Prevention and Treatment Center, and Professor Zhou Caicun of Shanghai Pulmonary Hospital Affiliated to Tongji University expressed their insights on the research and development of China's anti-tumor innovative drugs
.

Looking back on the past, China's successful experience in the research and development of innovative oncology drugs

Moderated by Professor Shen Lin (Photo)

Multiple panelists (photo)

Combined with the current situation of gynecological cancer diagnosis and treatment, Professor Wu Lingying said that the research and development of gynecological cancer drugs has undergone the development process
of "imitation-innovation-first in class".
Taking ovarian cancer as an example, PARP inhibitors have made milestones in the field of ovarian cancer, and their application options are gradually enriched
by innovative drugs developed and introduced by local enterprises.
In the future, the development of new targets and drugs based on clinical needs and the strengthening of basic and translational research are the direction of
joint efforts of colleagues in the field of oncology in the future.
In addition, how to organically combine existing treatment options is also the direction
of clinical oncologists.

Looking back on the history of the development of anti-tumor drugs, Professor Liang Jun lamented that in the past, the treatment options for patients with advanced liver cancer in China were limited, but with the emergence of innovative drugs such as apatinib, the survival benefits of this patient group have been significantly improved
.
The development of systematic treatment of liver cancer is only a microcosm
of the research and development achievements of anti-tumor innovative drugs in China.
Exploring the reasons behind the explosive development of innovative drugs is inseparable from the support of national policies, the continuous innovation of local enterprises and the silent efforts
of clinical oncologists.
It is precisely because of multi-party cooperation that China's innovative cancer drugs have gradually entered the international stage, allowing the world to hear the "Voice of China"
.

Looking forward to the future, establish a breakthrough point in the development of new anti-tumor drugs in China

Based on the current situation of innovative drug research and development of lymphoma, Professor Huang Huiqiang said that immune and targeted therapy is currently quite active in this field, whether it is CAR-T cell therapy or bispecific antibodies, which have achieved gratifying efficacy
in lymphoma.
In addition, some innovative drugs, such as antibody conjugates (ADCs), have also shown promising therapeutic prospects
.
It is expected that innovative drugs can be combined with classical therapeutic drugs in the future to provide patients with better treatment options
.

For the future development of oncology drugs, Professor Zhang Li believes that the next decade is a "blowout period" for the research and development of anti-tumor drugs in China, and innovative drugs such as targeted therapy, immunotherapy and ADC will be the focus of
new tumor drug research and development.
At the same time, the development of new drugs to support oncology therapy is also crucial
.
Most malignant tumors are difficult to cure, and how to extend the life of patients while ensuring the quality of life of patients and achieving the treatment goal of "living long and living well" still needs the joint efforts and exploration
of colleagues in the field of oncology.

Combined with the rapid development of lung cancer drugs in recent years, Professor Zhou Caicun said that although drugs targeting rare targets have been available, the efficacy of some drugs is still unsatisfactory, which is far
from the efficacy of first-line treatment of immunotherapy combined with chemotherapy.
How to improve the efficacy of targeted drugs and break through the bottleneck of immunotherapy has become one of the
important problems faced by clinicians.
Secondly, drug resistance is another urgent problem to be solved, and how to break the dilemma of primary and secondary drug resistance requires pharmaceutical companies and clinical experts to work together
.

Moderated by Professor Zhao Weiying (Photo)

Report by Professor Zhu Jun (Photo)

Hand in hand with Xingtu: Establish a new pattern of standardized diagnosis and treatment of hematological tumors in China

Under the chairmanship of Professor Zhao Weiying of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, the conference entered the second chapter
.
In the chapter of "Hand in Hand with the Stars", Professor Zhu Jun of Peking University Cancer Hospital delivered a speech
entitled "Establishing a New Pattern of Standardized Diagnosis and Treatment of Hematological Oncology in China".
Professor Zhu said that the 5-year survival rate of hematological lymphomas has made great progress, and these gratifying progress are mainly due to the standardization of the diagnosis and treatment of hematological lymphomas, the strengthening of multidisciplinary cooperation, the development of specialized specialties and the importance clinicians attach to
the whole process of patient health management.
In the past 70 years, China's hematological oncology has made remarkable achievements
in the fields of discipline construction and standardization of diagnosis and treatment.
At the same time, Professor Zhu Jun emphasized that there are still many unmet clinical needs on the road to standardization of the diagnosis and treatment of hematological tumors in China, such as uneven distribution of diagnostic resources, irregular treatment, and slow market launch of new drugs and high prices
.

In order to achieve the goal of "Healthy China", we should further strengthen multidisciplinary cooperation in the future, carry out the standardized promotion of tumor MDT, strengthen the safety of tumor drugs, improve patient compliance, optimize the new drug approval process, and help more new drugs access in China
.
At the same time, we should also pay attention to the economy of drugs and reduce the drug burden
for Chinese hematological cancer patients through medical insurance and commercial insurance.

Summit Dialogue: Focus on the new model of clinical multidisciplinary standardized diagnosis and treatment

Under the chairmanship of Professor Liu Lianxin of the First Affiliated Hospital of University of Science and Technology of China, Professor Feng Jifeng of Jiangsu Cancer Hospital, Professor Russell Xia of Henan Cancer Hospital, Professor Song Yongping of the First Affiliated Hospital of Zhengzhou University, Professor Jin Jie of the First Affiliated Hospital of Zhejiang University School of Medicine and Professor Yuan Xianglin of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology had a heated discussion
on the topic of "New Model of Clinical Multidisciplinary Standardized Diagnosis and Treatment".

Moderated by Professor Liu Lianxin (Photo)

Multiple panelists (photo)

Carrying on the past and forging ahead, MDT status analysis and trend exploration

In recent years, multidisciplinary collaborative diagnosis and treatment (MDT) has been greatly promoted
by the National Health Commission.
Professor Feng Jifeng pointed out that most hospitals have set up MDT outpatient clinics or MDT wards that focus on patients from multiple departments, which concentrate doctors from multiple departments to diagnose patients and provide patients with the best diagnosis and treatment plan
.
For patients with hematological cancers, MDT can bring better efficacy and safety
.
At present, nutrition and pain have been included in the MDT model, and the future MDT model will be patient-centered and develop
in the direction of improving the efficacy and quality of life of patients.
As the MDT model is gradually optimized, patients will benefit more
.

As an expert in the field of gastrointestinal tumors, Professor Russell Xia said that MDT has developed earlier in the field of gastrointestinal tumors, and MDT has covered ten common malignant tumors
.
Clinical practice suggests that MDT can significantly prolong the survival of
tumor patients.
In the future, the optimal treatment strategy determined through MDT will likely enable oncology patients to achieve the ultimate goal
of "living long and living well".

MDT is a hot issue in clinical discussions in recent years, and Professor Song Yongping believes that the diagnosis and treatment of lymphoma requires the participation of the MDT team to jointly formulate the best treatment plan
.
In the future, the development of MDT should be centered on the disease and the patient, and the treatment strategy should be formulated by considering the patient's factors, so as to take into account the prolongation of patient survival and the improvement
of quality of life.

Difficulties and challenges, MDT advantages and challenges

Professor Jin Jie introduced that the definitive diagnosis of hematological tumors is more complex, which usually involves multidisciplinary content
.
Therefore, MDT is essential
for the diagnosis and treatment of hematological cancers.
Based on clinical experience, MDT improves outcomes
in patients with hematological cancers.
The advantages of MDT are clearly visible, but it faces many challenges, such as how clinicians can concentrate on MDT under overload and how to improve clinicians' ability to ensure the quality of MDT
.

In addition to disease diagnosis and treatment, Professor Yuan Xianglin proposed that MDT can also be applied to the management
of immunotherapy-related adverse reactions.
In order to ensure the high quality of MDT, department doctors with rich clinical experience and high professional level should be sent to participate in MDT discussion
.
At the same time, an AB angle complement system should be set up to ensure the integrity
of MDT team members.
If MDT personnel are difficult to get together, this problem can also be solved through a smart platform
.
In addition, it is necessary to avoid authoritative experts dominating the entire MDT results during the MDT process, leading to diagnostic bias
.
For some simple cases, you can discuss through WeChat groups to save manpower
.

Summary of the meeting

At the end of the meeting, in a lively discussion atmosphere, the chairmen of the conference, Professor Liang Jun and Professor Liu Lianxin, concluded that although new anti-tumor drugs have emerged in recent years and the tumor diagnosis and treatment mode has been continuously innovated, the research and development of new drugs for tumors and the exploration of diagnosis and treatment models are still full of thorns, and the future research has a long way
to go.
It is believed that with the optimization and development of diagnosis and treatment methods, the field of cancer treatment in China will meet a better tomorrow
.

Summary of Professor Liang Jun and Professor Liu Lianxin (Photo)

In addition to the wonderful morning session, the afternoon session of this forum also has a number of sub-venues for comprehensive treatment of liver disease, diagnosis and treatment of special lymphoma, tumor supportive treatment and blood TCP management, providing a number of wonderful academic feasts
for the majority of oncologists.

Seminar on Comprehensive Treatment of Liver Disease

This conference is honored to invite Academician Fan Jia and Academician Teng Gaojun as the chairman, a number of experts and scholars around the comprehensive treatment of liver disease and the clinical application of Su Kexin ® conducted wonderful academic sharing and brainstorming, the content of the conference is both theory and practice, the participants benefited a lot
.

At the beginning of the conference, under the chairmanship of Professor Zhou Jian, Professor Sun Huichuan shared Su Kexin's ® two-year real-world research data and liver disease field guidelines/consensus updates
.
The conference arranged 3 academic chapters, sharing the treatment experience in the field of liver disease from different perspectives of research data, clinical experience and real cases, and the conference ended successfully in the heated discussion of participating experts
.

Special Lymphoma Diagnosis and Treatment Cloud Summit

Chaired by Professor Huang Huiqiang, Professor Li Jianyong, Professor Qiu Lugui, Professor Zhang Qingyuan and Professor Zhang Mingming, many experts and scholars conducted wonderful academic sharing and ideas on the progress of diagnosis and treatment of lymphoma, and the content of the conference was wonderful
.

The conference arranged two academic chapters, conducted in-depth discussions on the frontier progress, diagnosis and treatment experience and clinical challenges of special types of lymphoma, deepened the understanding of participating experts on the diagnosis and treatment of lymphoma, and provided strong support
for further promoting the development of lymphoma diagnosis and treatment.

Branch venue of the Oncology Supportive Care Seminar

Chaired by Professor Lin Tongyu, Professor Zhang Li and Professor Liang Jun, a number of experts and scholars shared wonderful academic sharing on the progress of tumor treatment in China and the application progress of Okonze ® and Su Kexin ® in the fields of chemotherapy-related vomiting (CINV) and thrombocytopenia (CTIT) caused by tumor treatment.

At the end of the conference, Professor Yuan Peng concluded that at present, China's emphasis on tumor supportive treatment management still needs to be further improved, and it is necessary to actively promote the concept of tumor supportive treatment in the future and improve the standardized diagnosis and treatment level
of supportive treatment.
Exploring the development of more new drugs and new diagnosis and treatment methods is also one of the
future development directions to support treatment.
In addition, Professor Yuan Peng thanked Fosun Pharma for its strong support, and called on domestic pharmaceutical companies to develop more new drugs and good drugs to benefit patients, as well as provide more platforms for experts in related fields to communicate
.

Blood TCP Management Summit Forum

The conference was chaired by Professor Wu Depei, Professor Zhang Liansheng, Professor Hou Ming, Professor Liu Qiqi and Professor Zhang Xiaohui, and a number of experts and scholars conducted wonderful academic sharing and discussions on the diagnosis and treatment of immune primary thrombocytopenia, aplastic anemia, hematopoietic stem cell transplantation and hematological tumor thrombocytopenia.

At the end of the conference, Professor Wu Depei, Professor Hou Ming and Professor Zhang Xiaohui summarized and commented on the academic content of the conference, and put forward higher expectations for the development of the field of blood therapy, and highly recognized the efficacy, safety and portability
of Avatrombopag compared with other thrombopoietin receptor agonists (TPO-RA).